Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-CVP vs R-CHOP vs R-FM in Stage II-IV Follicular Lymphoma
NCT00774826Phase 3Unknown
- Sponsor
- Fondazione Italiana Linfomi
- Start
- Dec 2005
- Primary completion
- Sep 2010
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of rituximab + cyclophosphamide + vincristine + prednisone, cyclophosphamide + doxorubicin + vincristine + prednisone + rituximab, fludarabine + mitoxantrone + rituximab in follicular lymphoma (FL), sponsored by Fondazione Italiana Linfomi. Status: unknown.
02
Drugs
rituximab + cyclophosphamide + vincristine + prednisonecyclophosphamide + doxorubicin + vincristine + prednisone + rituximabfludarabine + mitoxantrone + rituximab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT00774826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00774826.